[The effect of quinidine monotherapy and combined therapy with digoxin on the central hemodynamics in patients with heart rhythm disorders]. 1992

L L Orlov, and M G Glezer, and G I Tsintsadze, and I L Zaĭchik

The study was undertaken to examine 84 patients mainly with coronary heart disease and various cardiac arrhythmias. Quinidine monotherapy was found to normalize heart rate depending on its baseline values: it reduced heart rate in tachycardias and increased it in bradycardia. In patients with severe myocardial damage, especially in hypertension, quinidine decreased cardiac index, whereas total peripheral resistance increased. With quinidine, systolic pressure, stroke and cardiac indices showed a more decrease, whereas diastolic pressure and total peripheral resistance displayed a more increase in the standing position. Supplement of digoxin corrected negative quinidine-induced hemodynamic changes and orthostatic failures.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011802 Quinidine An optical isomer of quinine, extracted from the bark of the CHINCHONA tree and similar plant species. This alkaloid dampens the excitability of cardiac and skeletal muscles by blocking sodium and potassium currents across cellular membranes. It prolongs cellular ACTION POTENTIALS, and decreases automaticity. Quinidine also blocks muscarinic and alpha-adrenergic neurotransmission. Adaquin,Apo-Quinidine,Chinidin,Quincardine,Quinidex,Quinidine Sulfate,Quinora,Apo Quinidine,Sulfate, Quinidine
D004077 Digoxin A cardiotonic glycoside obtained mainly from Digitalis lanata; it consists of three sugars and the aglycone DIGOXIGENIN. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in ATRIAL FIBRILLATION and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666) Digacin,Digitek,Digoregen,Digoxina Boehringer,Digoxine Nativelle,Dilanacin,Hemigoxine Nativelle,Lanacordin,Lanicor,Lanoxicaps,Lanoxin,Lanoxin-PG,Lenoxin,Mapluxin,Boehringer, Digoxina,Lanoxin PG,Nativelle, Digoxine,Nativelle, Hemigoxine
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006439 Hemodynamics The movement and the forces involved in the movement of the blood through the CARDIOVASCULAR SYSTEM. Hemodynamic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000889 Anti-Arrhythmia Agents Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. Anti-Arrhythmia Agent,Anti-Arrhythmia Drug,Anti-Arrhythmic,Antiarrhythmia Agent,Antiarrhythmia Drug,Antiarrhythmic Drug,Antifibrillatory Agent,Antifibrillatory Agents,Cardiac Depressant,Cardiac Depressants,Myocardial Depressant,Myocardial Depressants,Anti-Arrhythmia Drugs,Anti-Arrhythmics,Antiarrhythmia Agents,Antiarrhythmia Drugs,Antiarrhythmic Drugs,Agent, Anti-Arrhythmia,Agent, Antiarrhythmia,Agent, Antifibrillatory,Agents, Anti-Arrhythmia,Agents, Antiarrhythmia,Agents, Antifibrillatory,Anti Arrhythmia Agent,Anti Arrhythmia Agents,Anti Arrhythmia Drug,Anti Arrhythmia Drugs,Anti Arrhythmic,Anti Arrhythmics,Depressant, Cardiac,Depressant, Myocardial,Depressants, Cardiac,Depressants, Myocardial,Drug, Anti-Arrhythmia,Drug, Antiarrhythmia,Drug, Antiarrhythmic,Drugs, Anti-Arrhythmia,Drugs, Antiarrhythmia,Drugs, Antiarrhythmic

Related Publications

L L Orlov, and M G Glezer, and G I Tsintsadze, and I L Zaĭchik
April 1987, Kardiologiia,
L L Orlov, and M G Glezer, and G I Tsintsadze, and I L Zaĭchik
April 1973, Fortschritte der Medizin,
L L Orlov, and M G Glezer, and G I Tsintsadze, and I L Zaĭchik
July 1979, Kardiologiia,
L L Orlov, and M G Glezer, and G I Tsintsadze, and I L Zaĭchik
January 1990, Vnitrni lekarstvi,
L L Orlov, and M G Glezer, and G I Tsintsadze, and I L Zaĭchik
January 1980, Acta medica Scandinavica,
L L Orlov, and M G Glezer, and G I Tsintsadze, and I L Zaĭchik
March 1989, Vrachebnoe delo,
L L Orlov, and M G Glezer, and G I Tsintsadze, and I L Zaĭchik
January 1969, Sovetskaia meditsina,
L L Orlov, and M G Glezer, and G I Tsintsadze, and I L Zaĭchik
January 1983, European journal of clinical pharmacology,
L L Orlov, and M G Glezer, and G I Tsintsadze, and I L Zaĭchik
January 1984, Anesteziologiia i reanimatologiia,
Copied contents to your clipboard!